Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 27 04:00PM ET
5.15
Dollar change
+0.14
Percentage change
2.79
%
IndexRUT P/E- EPS (ttm)-1.18 Insider Own3.69% Shs Outstand205.77M Perf Week-5.85%
Market Cap1.06B Forward P/E- EPS next Y-0.34 Insider Trans0.00% Shs Float198.55M Perf Month-12.27%
Income-226.54M PEG- EPS next Q-0.21 Inst Own84.62% Short Float15.38% Perf Quarter-15.30%
Sales331.41M P/S3.20 EPS this Y46.44% Inst Trans-1.64% Short Ratio9.23 Perf Half Y-29.93%
Book/sh-2.21 P/B- EPS next Y45.89% ROA-42.46% Short Interest30.55M Perf Year-39.13%
Cash/sh1.90 P/C2.72 EPS next 5Y44.80% ROE- 52W Range4.82 - 9.06 Perf YTD-14.02%
Dividend Est.- P/FCF- EPS past 5Y-3.73% ROI-61.73% 52W High-43.19% Beta1.90
Dividend TTM- Quick Ratio3.12 Sales past 5Y190.00% Gross Margin98.09% 52W Low6.96% ATR (14)0.32
Dividend Ex-Date- Current Ratio3.31 EPS Y/Y TTM11.37% Oper. Margin-31.29% RSI (14)45.95 Volatility6.11% 5.60%
Employees536 Debt/Eq- Sales Y/Y TTM22.37% Profit Margin-68.36% Recom1.33 Target Price13.82
Option/ShortYes / Yes LT Debt/Eq- EPS Q/Q19.91% Payout- Rel Volume0.83 Prev Close5.01
Sales Surprise3.81% EPS Surprise-26.07% Sales Q/Q17.42% EarningsFeb 26 BMO Avg Volume3.31M Price5.15
SMA20-2.38% SMA50-5.82% SMA200-18.41% Trades Volume2,990,374 Change2.79%
Date Action Analyst Rating Change Price Target Change
Nov-20-23Resumed JP Morgan Overweight $10
Sep-18-23Upgrade RBC Capital Mkts Sector Perform → Outperform $9 → $10
Aug-04-23Upgrade Jefferies Hold → Buy $11
Jul-13-23Upgrade BofA Securities Neutral → Buy $10
Feb-22-23Upgrade Needham Hold → Buy $14
Nov-02-22Upgrade Evercore ISI In-line → Outperform $14 → $16
Aug-05-22Downgrade Oppenheimer Outperform → Perform
Aug-05-22Downgrade Evercore ISI Outperform → In-line $14
Apr-18-22Downgrade Barclays Overweight → Equal Weight $22 → $13
Apr-11-22Downgrade BofA Securities Buy → Neutral $21 → $14
Mar-25-24 04:01PM
Mar-13-24 07:07AM
Mar-05-24 07:01AM
Mar-01-24 08:29AM
Feb-28-24 10:47AM
04:05AM Loading…
Feb-27-24 04:05AM
Feb-26-24 04:45PM
08:10AM
07:32AM
07:09AM
07:00AM
Feb-23-24 07:00AM
Feb-21-24 04:01PM
Feb-19-24 07:54AM
Feb-12-24 07:00AM
07:00AM Loading…
Feb-05-24 07:00AM
Feb-02-24 07:00AM
Jan-09-24 09:25AM
Jan-05-24 04:01PM
Jan-03-24 04:01PM
07:00AM
Dec-19-23 07:00AM
Dec-05-23 04:01PM
Nov-30-23 08:42AM
Nov-29-23 07:00AM
Nov-21-23 04:01PM
07:00AM
Nov-10-23 07:00AM
Nov-06-23 04:01PM
Nov-03-23 12:03PM
12:00PM Loading…
12:00PM
11:28AM
05:31AM
Nov-02-23 08:53AM
07:17AM
07:00AM
Oct-27-23 07:00AM
Oct-26-23 07:00AM
Oct-20-23 07:00AM
Oct-19-23 07:00AM
Oct-04-23 07:00AM
Sep-18-23 07:00AM
Sep-05-23 07:00AM
Aug-28-23 08:30AM
Aug-23-23 04:01PM
Aug-04-23 04:56PM
04:01PM
Aug-03-23 02:30PM
08:15AM
07:07AM
07:00AM
Jul-20-23 09:55AM
07:00AM
Jul-19-23 07:00AM
Jul-18-23 09:42AM
Jul-17-23 07:00AM
Jul-13-23 09:43AM
Jul-06-23 07:00AM
Jul-03-23 04:23AM
Jun-06-23 07:00AM
Jun-01-23 07:00AM
May-31-23 07:02AM
May-22-23 07:00AM
May-09-23 10:21AM
May-04-23 04:01PM
May-03-23 02:00PM
01:44PM
07:13AM
07:00AM
Apr-27-23 10:03AM
07:00AM
Apr-26-23 10:02AM
Apr-19-23 07:00AM
Apr-18-23 07:00AM
Apr-17-23 01:24PM
Apr-12-23 07:00AM
Apr-04-23 07:00AM
Mar-31-23 07:00AM
Mar-29-23 04:01PM
Mar-08-23 03:00PM
Mar-02-23 07:00AM
Feb-24-23 07:00AM
Feb-23-23 04:32PM
07:39AM
Feb-22-23 03:29PM
02:31PM
07:00AM
05:31AM
Feb-21-23 11:55AM
11:30AM
08:35AM
07:00AM
Feb-16-23 10:19AM
Feb-15-23 10:00AM
Feb-14-23 10:00AM
Feb-08-23 07:34AM
Feb-07-23 07:00AM
Feb-06-23 07:00AM
Feb-03-23 07:00AM
Jan-26-23 07:00AM
BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SANDERS MACHELLEDirectorJun 15 '23Sale7.984,00031,92025,611Jun 15 04:37 PM
Hutson Nancy JDirectorJun 14 '23Sale8.0412,866103,44381,818Jun 15 04:33 PM
Thackray Helen M.Chief R&D OfficerApr 03 '23Sale8.297,00058,030207,275Apr 05 04:33 PM